Can AI guide the pharma company about the tactical priorities of multichannel engagement?

In a pharma company, multichannel engagement is a dynamic and multi-faceted puzzle, which changes based on country, competitors, the strategic importance of the market for a pharma company, and many more factors.

As it becomes a critical component of a pharma company’s edge in engaging the HCPs, one pharma company found a problem with timely results. While it was using a traditional market research approach to assess impact, the commercial excellence team at the pharma company had 2 asks: make it real-time, and quarterly instead of annual to ensure they could course correct.

When the pharma company found Graphene AI to be a viable, cost-effective real-time solution to meet these needs, they started a pilot to find out how it compared with their current way of measuring.

Today, this pharma company uses Graphene AI widely across all its divisions and countries—and gains an immediate tactical advantage in its ability to engage HCPs better, given the constant tactical recommendations our team of domain experts have trained the AI to deliver for the pharma company.